SSI Diagnostica

SSI Diagnostica is a globally active commercial-stage leader in in vitro diagnostics (IVD), providing high-quality solutions for disease prevention, surveillance, laboratory diagnosis, and vaccine quality control (QC) across infectious disease segments. They supply antisera and reagents for vaccine development, robust PCR and lateral flow assays, and key products for gastro, respiratory, and bloodborne infection detection. The company was previously a division of Statens Serum Institut and became independent in 2016 after acquisition by Adelis Equity. It expanded its international reach significantly with the acquisition of CTK Biotech in 2020.